CARSKNKDC (CAR) peptide, our lead therapeutic candidate, is being developed for the enhanced survival and treatment of pulmonary hypertension, COVID-19 and sepsis patients. CAR preferentially homes to, and penetrates diseased tissue while selectively augmenting the efficacy of therapies. CAR can selectively boost drug effectiveness and reduce systemic side effects by enhancing the targeted uptake of co-administered and conjugated therapeutics.

Our first interventional product, the endoarterial biopsy catheter, is the world’s first interventional device to obtain a biopsy sample from the inner layers of an artery in a minimally invasive fashion. Endoarterial biopsies will better enable the diagnosis, monitoring, and treatment of vascular-based diseases, and provide the synergy to develop a wide range of products, services, and pharmaceuticals that target vascular-based diseases.

Our molecular diagnostic products will provide molecular analyses of endoarterial biopsy samples, and a comprehensive profile of a patient’s vascular disease. We will extend the modern cancer care model of performing transcriptional profiling of tumor biopsies to diseases of the vasculature.